drugset / Trial / NCT06271252
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
NaSingle-groupOpen-labelTreatment
Summary
The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma. RIGEL Study
Timeline
- Start
- 2024-04-03
- Primary completion
- 2026-12-12
- Completion
- 2028-04-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OriCAR-017 | Cell therapy | — | Intravenous |